Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells

Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells

The current FDA-approved whole blood stabilization method for circulating tumor cell (CTC) isolation suffers from RNA degradation. Here the authors combine hypothermic preservation and antiplatelet strategies to stabilize whole blood up to 72 h without compromising CTC yield and RNA integrity.

Guardado en:
Detalles Bibliográficos
Autores principales: Keith H. K. Wong, Shannon N. Tessier, David T. Miyamoto, Kathleen L. Miller, Lauren D. Bookstaver, Thomas R. Carey, Cleo J. Stannard, Vishal Thapar, Eric C. Tai, Kevin D. Vo, Erin S. Emmons, Haley M. Pleskow, Rebecca D. Sandlin, Lecia V. Sequist, David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Shannon L. Stott, Mehmet Toner
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/2cb65508990f455f91b7d509541cd82f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The current FDA-approved whole blood stabilization method for circulating tumor cell (CTC) isolation suffers from RNA degradation. Here the authors combine hypothermic preservation and antiplatelet strategies to stabilize whole blood up to 72 h without compromising CTC yield and RNA integrity.

Ejemplares similares